Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 33c, Beats on Revenue; Offers FY24 Revenue Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.44 --0%
Revenue Growth %: +6.2%
Financial Fact:
Research and development: 2.49M
Today's EPS Names:
PKE, LNN, More
Revenue Growth %: +6.2%
Financial Fact:
Research and development: 2.49M
Today's EPS Names:
PKE, LNN, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.56, $0.33 better than the analyst estimate of $0.23. Revenue for the quarter came in at $122.7 million versus the consensus estimate of $111.77 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2024 revenue of $455-475 million, versus the consensus of $462.4 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla Q2 deliveries reach 480,126, topping estimates of 406,024
- Moomoo launches paid trading toolkit called Moomoo Engine
- Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
